Statement of Principles concerning carpal tunnel syndrome (Reasonable Hypothesis) (No. 93 of 2021)

This SoP frames causation for administrative claims under the VEA and MRCA by defining a clinical entity, listing discrete factors that can establish a reasonable hypothesis of causal connection to service, and specifying temporal and quantitative thresholds for those factors.

Clinical meaning: The instrument supplies a clinical definition of carpal tunnel syndrome for the purposes of these claims: an entrapment neuropathy of the median nerve at the wrist producing altered sensation, pain or weakness of the hand (s 7(2)). Although CTS attracts ICD‑10‑AM code G56.0, the instrument explicitly states that the meaning used is the clinical definition in s 7(2), with the ICD reference noted but not determinative (s 7(3)-(4)).

Two causation pathways: The SoP distinguishes between causation (s 9(1)-(17)) and material contribution or aggravation (s 9(18)-(35)), and links each to relevant service as required by s 10. Section 10(2) clarifies that the factors in subsections 9(18) to 9(35) apply only to material contribution or aggravation where the person’s CTS was suffered or contracted before or during, but did not arise out of, the person’s relevant service.

Objective thresholds and timing: The instrument imposes quantifiable exposure thresholds. Example: specified activities with the affected hand or forearm must have been performed for an average of at least 8 hours per week and for a cumulative period of at least 6 months before clinical onset, with a 30‑day rule if exposure ceased before onset (s 9(1); s 9(18)). Specified activities are defined in Schedule 1 in concrete terms, such as repetitive movements involving bending or twisting the hand or wrist at least 50 times per hour, forceful activities exceeding certain load parameters, activities where the hand is directly vibrated, or hand‑weight‑bearing activities (Schedule 1).

Non‑occupational medical contributors: The instrument lists a catalogue of medical conditions and circumstances that, if present at the time of clinical onset or clinical worsening, satisfy the “factors that must exist” test. These include overweight or obesity (Schedule 1 definition of BMI and waist circumference thresholds), amyloidosis, chronic renal failure (strict GFR or dialysis criteria in Schedule 1), hypothyroidism or Hashimoto thyroiditis, acromegaly, gout, space‑occupying lesions, haemorrhage into the carpal tunnel (with examples), infection involving the carpal tunnel (with examples), osteoarthritis or inflammatory arthritis, diabetes mellitus, certain medications within defined look‑back periods (aromatase inhibitors and immune checkpoint inhibitors within 2 years), and pregnancy within three months (s 9(4)-9(17); s 9(20)-9(35); Schedule 1 definitions).

Trauma and anatomical change: Trauma or surgery that alters the contour of the carpal tunnel or damages flexor tendons is a listed factor for both onset and worsening (s 9(2); s 9(19)). Schedule 1 supplies a definition of trauma that requires a discrete event with specified onset and persistence of symptoms and allows medical intervention to alter the persistence requirement (Schedule 1).

Death from CTS: The SoP includes death from CTS when a terminal event or condition was contributed to by the CTS, and defines “terminal event” by listing proximate causes such as pneumonia, respiratory failure, cardiac arrest, circulatory failure and cessation of brain function (s 7(5); Schedule 1).

Interaction with other SoPs: Section 11 provides that if a factor in this SoP refers to an injury or disease covered by another SoP determined under subsection 196B(2) of the VEA, the factors in that other SoP apply in accordance with its terms as in force from time to time. This creates an explicit cross‑reference mechanism where overlapping conditions are regulated by separate Statements.

Standard of proof and role in claims: The instrument is designed to establish whether a “reasonable hypothesis” has been raised that CTS is related to relevant service. The instrument itself states the Repatriation Medical Authority’s view of the medical‑scientific evidence base (s 8). The SoP therefore operates as forensic guidance in the administrative claims process under the VEA and MRCA rather than as a statute creating offences or payment rates.

Direct claimants: The instrument applies to persons lodging claims where section 120A of the VEA or section 338 of the MRCA applies (s 5). That captures veterans and other persons whose entitlement claims under those statutory provisions involve allegations that CTS or death from CTS is connected to relevant service. The Schedule 1 definition of “relevant service” identifies the classes of service covered: operational service, peacekeeping service, hazardous service, British nuclear test defence service under the VEA, and warlike or non‑warlike service under the MRCA (Schedule 1, relevant service). Thus, active duty and former members whose service meets those statutory categories may be affected.

Decision makers and medical assessors: The Repatriation Medical Authority has made the instrument (s 3). Although the instrument does not itself identify the body that decides claims under the VEA and MRCA, the SoP is intended to be applied within those claims processes (s 5). Medical practitioners, occupational physicians, and administrative decision makers who adjudicate VEA/MRCA claims will use the clinical definition (s 7(2)), the exposure thresholds and timing rules (s 9; Schedule 1), and the Schedule definitions to assess whether a reasonable hypothesis exists.

Employers, insurers and third parties: While the instrument does not create direct obligations for private employers or insurers, its concrete thresholds for specified activities and definitions of trauma, obesity and other medical contributors will shape evidentiary expectations in claims that may have knock‑on effects for private parties. For example, occupational histories demonstrating average weekly exposure, task frequency (50 times per hour), force thresholds (>3 kg) or vibration exposures may become relevant evidence. Employers and insurers may need to produce or preserve records showing the duration and intensity of tasks performed by claimants to support or contest claims.

Healthcare providers: The SoP’s reliance on clinical signs, diagnostic criteria and defined comorbidities places responsibility on treating clinicians to record required elements. Examples in the Schedule (such as examples of infections, space‑occupying lesions, haemorrhage causes, and drug examples) indicate the type of diagnostic detail that will support or undermine a claim. BMI is explicitly defined and calculated as W/H2 (Schedule 1), so providers who record height and weight enable application of the instrument’s overweight/obese factor.

Service organisations and record keepers: Service records that document the nature and timing of duties, exposure to repetitive tasks, trauma, surgeries, or exposure to vibration will be material. The 30‑day rule for onset after cessation of activities (s 9(1); s 9(18)) and cumulative exposure windows (6 months) increase the importance of contemporaneous service records.

Beneficiaries and intermediaries: Claim preparers, legal representatives, advocates and allied health professionals preparing claims must align submissions to the precise thresholds and definitions in the SoP. Where a factor refers to an injury or disease covered by another SoP, the other SoP applies in its terms (s 11), thereby affecting cross‑condition claims and requiring familiarity with multiple Statements.

Indirectly affected groups: The instrument has potential indirect effects on rehabilitation services and procurement where claims and medical management of CTS influence service demand. Additionally, veterans who have CTS that pre‑existed service but were exposed to aggravating factors during service will be affected because sections 9(18)-9(35) and 10(2) create a route for material contribution or aggravation claims.

Absent groups: The SoP does not itself alter the underlying statutory eligibility thresholds for payment, nor does it create new offences or administrative penalties. It also does not apply to non‑service‑related claims outside the VEA and MRCA frameworks.

The instrument is not framed as a statute imposing duties on private parties. Instead, it creates standards and definitions that operate within the duties and rights architecture of the VEA and MRCA claims regimes. The primary legal effects derive from how the SoP is used by decision makers to determine whether a reasonable hypothesis exists that CTS or death from CTS is related to relevant service.

Duty to satisfy the SoP for a reasonable hypothesis: For a claimant to raise a reasonable hypothesis that CTS is related to relevant service, at least one of the factors listed in section 9 must exist (s 9 introductory text). The duty, therefore, is evidential: claimants must adduce material establishing one or more of the listed factors and show it is related to relevant service (s 10(1)). Where the claimant relies on factors in subsections 9(18)-9(35), those factors apply only to material contribution or aggravation where CTS was suffered or contracted before or during, but did not arise out of, the person’s relevant service (s 10(2)).

Duty to relate factors to relevant service: Section 10(1) imposes a relational requirement: any factor relied on from section 9 must be related to the person’s relevant service. The instrument leaves the mechanics of that relational proof to the claims process under the VEA and MRCA, but the SoP supplies the substantive elements the decision maker will examine.

Duty to consider overlapping SoPs: Section 11 requires that where a factor in this SoP refers to an injury or disease covered by another SoP under subsection 196B(2) of the VEA, the factors in that other SoP apply according to its terms as in force from time to time. That imposes a duty on decision makers and claim preparers to identify cross‑referenced conditions and apply the other SoP’s factors.

Rights of claimants: The instrument provides the claimant the right, within the administrative claim process, to rely on any of the enumerated factors to raise a reasonable hypothesis. The SoP supplies a roadmap for what constitutes sufficient medical‑scientific connection for CTS in the context of relevant service. The claimant has a right to have decision makers assess whether the SoP’s factors are met in the claim.

Rights and obligations of medical practitioners: The instrument’s definitions and thresholds, such as the clinical definition of CTS (s 7(2)), the BMI calculation (Schedule 1), trauma criteria (Schedule 1) and chronic renal failure criteria (Schedule 1), create obligations for clinicians who provide evidence to collect and report the specified elements accurately. Decisions under the VEA/MRCA will typically require medical evidence that aligns to these definitions.

No express duties to third parties or penalties in the SoP: The instrument does not impose duties on employers, nor does it include prosecution or penalty provisions within its text. Its legal force is that of a determinative medical statement used for assessing claims under other statutes. Any enforcement, penalties or administrative procedures remain those provided under the VEA and MRCA and their implementing regulations and decision frameworks, given that the SoP is made under subsection 196B(2) of the VEA and explicitly applies to claims under particular sections of the VEA and MRCA (s 3; s 5).

Evidentiary implications: The SoP specifies precise temporal and quantitative thresholds, such as the 8 hours per week average and 6 months cumulative exposure for specified activities (s 9(1); s 9(18)), the 30‑day post‑cessation timing rule (s 9(1); s 9(18)), and the detailed Schedule definitions (for example, repetitive movements of at least 50 times per hour or forceful activities >3 kilograms). These thresholds effectively structure what medical and occupational evidence is necessary for claimants to establish their rights within the claims process.

The Statement of Principles itself does not create criminal offences, civil penalties or administrative sanctions. The instrument functions as medical criteria for determining whether a reasonable hypothesis exists that CTS or death from CTS is related to relevant service (s 3; s 8). It applies to claims to which section 120A of the VEA or section 338 of the MRCA apply (s 5), and therefore enforcement and remedies, including any penalties for false statements or improper claims, are those provided under the VEA and MRCA and their implementing frameworks, not within this SoP.

Operational enforcement: Practically, the SoP will be enforced administratively through the claims processes of the relevant statutory schemes. Decision makers will apply the SoP’s definitions, thresholds and temporal rules when assessing medical causation. A claim accepted as raising a reasonable hypothesis that CTS is related to relevant service will then proceed to the statutory decision stage under the VEA or MRCA. The SoP does not itself prescribe the subsequent administrative steps, appeal routes or review mechanisms; those are contained in the VEA, the MRCA and associated procedural instruments.

Evidential consequences rather than sanctions: The main enforcement mechanism built into the instrument is evidentiary: if claimants cannot demonstrate any of the factors listed in section 9, or cannot show relation to relevant service per section 10, then the requisite reasonable hypothesis will not be established. Failure to meet the criteria thus has the administrative consequence of an unsuccessful causation element in a claim, which in turn affects entitlement decisions under the VEA/MRCA. The instrument therefore operates by setting thresholds that, if unmet, deny further progress on causation within the claims process.

Role of other Statements and cross‑application: Section 11 provides that if a factor in this SoP refers to a disease or injury covered by another SoP made under subsection 196B(2) of the VEA, the other SoP’s factors apply in accordance with its terms as in force. This means enforcement of causation in cases involving overlapping conditions may require application of multiple SoPs, each of which structures the evidentiary hurdle.

No express inspectorate, compliance notices or fines: The instrument does not establish a compliance regime with audits, notices, or fines. It is a technical medical statement intended to be applied by adjudicators and medical assessors. Any regulatory enforcement activity, penalties for non‑compliance with administrative obligations, or sanctions for fraudulent claims must be found in the VEA or MRCA themselves, not in this instrument.

Practical enforcement risks and burdens: The SoP’s prescriptive thresholds create a predictable but demanding evidentiary regime. It will be for administrative decision makers to insist on medical and occupational evidence that concretely maps to the instrument’s definitions and timing rules. That places an operational enforcement burden on adjudicators to evaluate the sufficiency and reliability of occupational histories, medical records, imaging, surgical notes, pharmaceutical histories and biometric data such as BMI. The SoP thereby shifts enforcement into evidentiary gatekeeping rather than statutory penalty imposition.

This instrument is made under subsection 196B(2) of the Veterans' Entitlements Act 1986 and explicitly applies to claims to which section 120A of the VEA or section 338 of the Military Rehabilitation and Compensation Act 2004 applies (s 3; s 5). It thus functions as a medico‑legal input to the VEA and MRCA administrative frameworks rather than as an independent source of entitlements or sanctions.

Dependence on VEA and MRCA claims processes: The SoP does not itself authorise payments or define benefit rates. Any consequence of the SoP is realised through the VEA/MRCA processes: if a reasonable hypothesis is raised under the SoP, the claimant proceeds to the statutory decision makers who apply the VEA or MRCA to determine entitlements and other outcomes. The SoP supplies medical criteria to be used in those determinations (s 5).

Cross‑relationships with other Statements of Principles: Section 11 provides a direct mechanism for interaction with other SoPs made under subsection 196B(2) of the VEA. If a factor in this instrument refers to an injury or disease covered by another SoP, the factors in that other SoP apply according to its terms as in force from time to time. That creates the need for decision makers to consult and apply multiple SoPs where comorbidity or causation is shared across conditions.

ICD‑10‑AM code reference and clinical primacy: The instrument notes that while CTS attracts ICD‑10‑AM code G56.0, the meaning for these purposes is the clinical definition in subsection 7(2) (s 7(3)-(4)). The instrument therefore interacts with broader diagnostic coding schemes by referencing them but confirming that the clinical description governs within this instrument’s application.

Interface with medical and pharmaceutical regulation: The SoP lists medications (for example aromatase inhibitors and immune checkpoint inhibitors, with examples in the notes) as factors that may be relevant within two‑year look‑back windows (s 9(15); s 9(16); s 9(32); s 9(33)). Practitioners and decision makers applying the SoP will therefore need to map pharmaceutical treatment histories to the instrument’s criteria; this intersects with prescription records and any privacy or medical records legislation governing access to such information.

Intersection with occupational health and safety law: The instrument defines specified activities in concrete occupational terms (Schedule 1). While the SoP does not modify workplace safety duties, the occupational exposure thresholds it establishes for claims may bring workplace records and employer evidence into play during claim adjudication. Employers and insurers may therefore be required to produce task rosters, risk assessments, or other workplace documentation, subject to whatever disclosure regimes apply under other laws or administrative processes.

Evidence law and administrative process rules: Though the SoP sets out the medical requirements for a reasonable hypothesis, the process by which that hypothesis is evaluated is governed by the evidentiary and procedural rules of the VEA and MRCA decision frameworks. This instrument does not create or modify those evidentiary rules. Decision makers will need to apply administrative law principles and the statutory evidentiary standards of the underlying Acts when using the SoP.

No conflict clause or overriding provision: The instrument does not contain a clause stating it overrides other law. Its legal effect is as a statutory instrument made under specific authority and as an input to the VEA/MRCA claims process. Section 11 already contemplates interaction with other SoPs, but the instrument does not purport to displace general laws governing medical practice, privacy, or administrative procedure.

Date and instrument identifiers: The instrument identifies itself as the Statement of Principles concerning carpal tunnel syndrome (Reasonable Hypothesis) (No. 93 of 2021) and is dated 20 August 2021 on its face. It commences on 20 September 2021 (s 1; s 2; front matter). The instrument was made under subsection 196B(2) of the Veterans' Entitlements Act 1986 (s 3).

Repeal of prior Statement: Section 4 expressly repeals the Statement of Principles concerning carpal tunnel syndrome No. 7 of 2013 (Federal Register of Legislation No. F2013L00022). That is the only repeal recorded in the instrument. No other amendments to prior SoPs are noted within the instrument. The repeal indicates that the 2021 instrument replaces the 2013 SoP for applications covered by the VEA and MRCA references in s 5.

No further amendment schedule in the instrument: The document contains no schedule of future amendments or sunset provision. It does, however, state in s 11 that where a factor in this SoP refers to an injury or disease covered by another SoP determined under subsection 196B(2) of the VEA, the factors in that other SoP apply as in force from time to time. That language expressly anticipates that other SoPs may be amended independently and that those amendments will affect cross‑referenced application.

Authority and formalities: The instrument bears the Common Seal of the Repatriation Medical Authority and a Chairperson signature block (front matter). The instrument’s authority derives from subsection 196B(2) of the VEA. The Schedule supplies dictionary definitions which are integral to the operative text and thus part of the instrument on commencement.

No recorded subsequent amendments in this text: The provided instrument contains the 2021 text and the repeal of the 2013 instrument but does not record any later amendments, consolidations, or revocations. To identify any later modifications after commencement, one must consult the Federal Register of Legislation or the Repatriation Medical Authority’s current publications; no such subsequent modifications are present within the supplied text.

Examples used as non‑exhaustive clarifications: The instrument includes multiple notes and examples in both the main body and Schedule 1 (for example examples of space‑occupying lesions, infections, haemorrhage situations, and examples of aromatase inhibitors and immune checkpoint inhibitors). These illustrative notes do not appear as standalone amendments but are part of the operative explanatory material present at commencement.

The instrument itself contains no litigation history and does not cite any judicial decisions. It is an administrative medical statement made by the Repatriation Medical Authority under statutory power (s 3). The text records the Authority’s view regarding the medical‑scientific evidence base (s 8), but the instrument does not refer to any court rulings, tribunal decisions or precedent cases that bear on its content.

Implication for litigated claims: Although the SoP is an administrative instrument, it will be used in statutory claims under the VEA and MRCA. Those decisions may be subject to merits review, administrative law challenges or judicial review in relevant courts and tribunals. The instrument itself does not identify or report outcomes of such reviews. Any litigation that tests the application of this SoP will therefore be found in external case law and tribunal decisions, not within the instrument.

No binding judicial interpretation referenced: The SoP does not incorporate or rely on meanings established by judicial interpretation. Its definitions and thresholds are self‑contained (for example Schedule 1 definitions of specified activities, trauma, BMI, chronic renal failure), so the initial application and enforcement will rest on administrative interpretation guided by the instrument’s language.

Cross‑SoP litigation potential: Section 11’s cross‑reference to other SoPs suggests factual situations in which disputes will require comparison of multiple Statements. This creates potential for litigation where overlapping medical conditions and differing SoP thresholds interact. The instrument itself does not resolve conflict; that remains for adjudicators and, potentially, courts.

Absence of recorded challenges within the instrument: Because the instrument is self‑contained and the supplied text records no challenges, readers should not infer litigation history or precedent from this document. Any assessment of how courts or tribunals have treated this SoP would require searching external judicial and tribunal records, which are not contained in the present text.

Precise timing and cessation rules: The instrument’s causal exposure thresholds include specific timing rules that can be decisive. For specified activities, the claimant must show an average of at least 8 hours per week and a cumulative period of at least 6 months before clinical onset or worsening (s 9(1); s 9(18)). If those activities ceased before onset or worsening, the clinical event must have occurred within 30 days of cessation (s 9(1); s 9(18)). These are strict temporal formulations. If exposures fall short of the 6‑month cumulative or the 8‑hour weekly average, or if onset occurs outside the 30‑day post‑cessation window, the SoP’s specified activities factor will not be satisfied.

Granularity of “specified activities” and task measurement: Schedule 1 defines specified activities in workplace‑measurable terms, such as repetitive movements involving bending or twisting of the hand or wrist at least 50 times per hour, or forceful activities requiring generation of force equivalent to lifting or carrying more than 3 kilograms, or lifting objects in excess of 1 kilogram more than 10 times per hour (Schedule 1). This level of granularity demands contemporaneous task data or credible reconstruction. Generalised statements about repetitive work will not automatically meet these objective thresholds.

Onset versus worsening distinction and limitation on aggravation factors: Sections 9(1)-9(17) list factors relevant to onset, whereas sections 9(18)-9(35) list factors for clinical worsening or material contribution to aggravation. Section 10(2) limits application of subsections 9(18)-9(35) to cases where CTS was suffered or contracted before or during, but did not arise out of, the person’s relevant service. In other words, the path to entitlements for aggravation is narrower and depends on a pre‑existing condition. Misunderstanding this distinction can lead to misframed claims.

Clinical definition takes precedence over ICD code: Although the instrument notes the ICD‑10‑AM code G56.0 (s 7(3)-(4)), it insists the operative meaning is the clinical definition in s 7(2). A pure reliance on coding without clinical detail on altered sensation, pain or weakness may be insufficient.

Trauma definition’s conditional persistence rule: The Schedule’s definition of trauma requires the development of symptoms within 24 hours and persistence for at least 7 days, except where medical intervention occurred and involved immobilisation, injection, or surgery (Schedule 1, trauma). This is a technical test that combines timing, persistence and procedural exceptions, and may be overlooked if relying on lay descriptions of injury.

BMI calculation and waist circumference thresholds: “Being overweight or obese” uses specific thresholds: BMI ≥25 or waist circumference exceeding 94 cm for males or 80 cm for females (Schedule 1). The instrument gives the BMI formula W/H2. Claims that assert obesity must supply measured height and weight or medical records sufficient to compute BMI; subjective impressions are insufficient.

Chronic renal failure criteria are strict: Schedule 1 defines chronic renal failure by a GFR threshold (<15 mL/min/1.73 m2 for at least three months), a need for renal replacement therapy for complications, or undergoing chronic dialysis. Documentary biochemical or dialysis records will typically be necessary. General references to “kidney problems” do not meet the SoP’s defined threshold.

Medication look‑back windows: The instrument requires that aromatase inhibitors or immune checkpoint inhibitors be taken within the 2 years before clinical onset or clinical worsening (s 9(15)-9(16); s 9(32)-9(33)). Pharmacy dispensing records or oncological treatment summaries will be required to show timing. The instrument provides examples of the drugs (notes under those subsections), which help identify relevant medications.

Pregnancy window: Being pregnant within the 3 months before clinical onset or worsening is a listed factor (s 9(17); s 9(34)). Recordation of pregnancy dating will be relevant evidence.

Death causation complexity: The instrument includes death from CTS where death results from a terminal event or condition contributed to by CTS (s 7(5)). It lists examples of terminal events (Schedule 1) but does not create a simple causal chain. For death claims, claimants must show contribution of CTS to the terminal event, which will require rigorous medical evidence.

Cross‑SoP application risk: Section 11 requires application of other SoPs if the factor refers to a disease covered by such an SoP. This means a factor that appears simple in isolation might trigger more complex evidentiary and legal regimes under another Statement, increasing complexity for claimants and decision makers.

No penalties in SoP: The instrument provides no penalty provisions; its failure to set enforcement mechanisms beyond evidentiary gates means the practical “penalty” for non‑compliance is claim denial. Parties should not expect the SoP to provide coercive enforcement or supervisory remedies.

Examples are illustrative not exhaustive: The instrument contains numerous “Note: Examples” entries (for example infections, space‑occupying lesions, haemorrhage causes, and examples of implicated drugs). These are illustrative, not limiting; the text does not state they are exhaustive. However, reliance on non‑listed or unusual causes will require closer medical substantiation.

Administrative burden: The combination of clinical, timing, occupational and pharmacological thresholds creates a detailed evidentiary picture that can impose significant record‑gathering burdens on claimants, medical practitioners and administrative decision makers.

Gather precise clinical evidence matching the clinical definition: Obtain a clear clinical diagnosis that aligns with the instrument’s operative definition of carpal tunnel syndrome as an entrapment neuropathy of the median nerve at the wrist producing altered sensation, pain or weakness of the hand (s 7(2)). While the ICD‑10‑AM code G56.0 is mentioned, the clinical definition governs (s 7(3)-(4)). Clinical notes should describe signs and symptoms, diagnostic studies (for example nerve conduction studies if performed), and any imaging or surgical findings that demonstrate median nerve entrapment.

Document temporal and quantitative exposure data for specified activities: If relying on the specified activities factor (s 9(1); s 9(18)), collect contemporaneous records or credible reconstructions that show the claimant performed the specified activities for an average of at least 8 hours per week and for a cumulative period of at least 6 months prior to clinical onset or worsening. Map job tasks to Schedule 1 definitions: repetitive movements at least 50 times per hour, forceful activities exceeding 3 kg load or lifting >1 kg >10 times per hour, direct vibration exposure, or weight‑bearing activities (Schedule 1). If activities ceased before onset or worsening, document the cessation date and show the clinical onset/worsening occurred within 30 days of cessation (s 9(1); s 9(18)).

Capture trauma and surgical records precisely: For trauma or surgery factors (s 9(2); s 9(19)), secure acute injury records that establish a discrete event with onset of symptoms within 24 hours, persistence for at least 7 days, and any medical interventions such as immobilisation, corticosteroid injection or surgery (Schedule 1, trauma). Obtain operative notes, emergency department records, imaging and follow‑up notes to demonstrate the anatomical changes or tendon damage described by the SoP.

Record comorbidities and biometric measures as defined: For factors such as being overweight or obese, compute BMI using W/H2 and document waist circumference where available; the BMI threshold is ≥25 or waist circumference >94 cm for males and >80 cm for females (Schedule 1). For chronic renal failure, produce GFR records demonstrating <15 mL/min/1.73 m2 for at least three months, dialysis or transplantation records, or notes showing a need for renal replacement therapy (Schedule 1). For inflammatory conditions (for example inflammatory arthritis), secure diagnostic and treatment records confirming autoimmune inflammatory disease and any disease‑modifying therapy where applicable (Schedule 1).

Obtain pharmaceutical and treatment histories: If allergic to or taking medications listed in the SoP (a aromatase inhibitor or an immune checkpoint inhibitor), obtain oncology or pharmacy dispensing records that show timing within the 2‑year window before onset or worsening (s 9(15)-9(16); s 9(32)-9(33)). The instrument provides examples of these drugs, which can guide record searches.

Document pregnancy and other time‑limited biological states: For pregnancy within three months before onset or worsening (s 9(17); s 9(34)), provide obstetric records, pregnancy test results, antenatal notes and gestational dating.

Demonstrate oedema, haemorrhage, infection, space‑occupying lesions and arthritis where relevant: For factors that involve local anatomical or pathological states (s 9(3); s 9(10); s 9(11); s 9(12); s 9(13); s 9(26)), collect imaging reports, histopathology, microbiology, surgical findings and specialist reports that identify oedema, lesions, haemorrhage, infection or arthritis in the affected carpal tunnel, wrist or hand. The instrument provides example lists to guide possible causes (Notes under each subsection).

Map exposures and events to relevant service: Under s 10(1) any factor relied on must be related to the person’s relevant service. Collect service records, duty rosters, deployment logs, unit task descriptions, equipment lists, and witness statements that link exposures, tasks, trauma or surgeries to the claimant’s relevant service as defined in Schedule 1. For aggravation claims under s 10(2), demonstrate that CTS pre‑existed or was contracted before or during service but did not arise out of service, and that the relevant service materially contributed to worsening by reference to the factors in subsections 9(18)-9(35).

Check for cross‑referenced SoPs: If a factor refers to another injury or disease covered by another SoP, identify that SoP and apply its factors in claims submissions as required by s 11. This may require additional medical or factual material specific to the other SoP.

Provide a clear causal narrative: Link the clinical diagnosis, the timing of onset or worsening, the presence of one or more listed factors, and the relationship to relevant service in a coherent narrative. Demonstrate each element of the SoP you rely upon with documentary evidence that maps to the instrument’s technical definitions and timing rules.

Anticipate evidentiary rebuttal: Because the SoP sets objective thresholds, prepare to refute alternative explanations by supplying contemporaneous records that directly meet the SoP criteria. For example, where an employer may contest the intensity of repetitive work, supply task analyses, ergonomic assessments, timeallocation records, or co‑worker statements consistent with Schedule 1 thresholds.

Use clinical specialists where required: When the SoP refers to specialised medical states (for example amyloidosis, acromegaly, or chronic renal failure), obtain specialist reports and laboratory or imaging confirmation. For death claims, coordinate medico‑legal and specialist evidence to establish contribution of CTS to the terminal event (s 7(5); Schedule 1 terminal events).

Preserve records and measure biometrics contemporaneously: Where possible, retain contemporaneous measurements of height, weight and waist circumference, and document GFR or dialysis status, to avoid retrospective disputes over thresholds such as BMI or chronic renal failure criteria.

Engage with the statutory claims framework: Remember that the SoP feeds into claims under the VEA and MRCA (s 5). Prepare submissions that align SoP‑compliant medical and service evidence with the procedural and evidentiary rules of the relevant claims process.

Consider multiple SoPs and comorbidities: If a factor links to another SoP under s 11, prepare evidence that meets both instruments’ requirements. Cross‑condition claims can require additional documentary and medical material.

Seek specialist advice for complex cases: For unusual causes, equivocal timing, or multiple interacting factors, obtain detailed specialist reports that explicitly reference the SoP criteria and explain how the case meets them, particularly for subtle issues such as material contribution to worsening under s 10(2).

By methodically aligning medical documentation, service records and occupational evidence to the instrument’s precise definitions and timing rules, claimants and their advisers can ensure submissions present the most direct mapping to the Repatriation Medical Authority’s Statement of Principles.